| karatu # | Marubuci, taken nazari, url link PDF, babban abin da aka gano akan fa'idar wannan magani a cikin kayan aikin jiyya da wuri. |
| Sunan likitanci: IVERMECTIN (duba Hoto na 1 da bayanin kula akan ivermectin don kula da marasa lafiya da kuma jagora ga likitocin, don Allah latsa nan.) |
| 1) | Espitia-Hernandez G et al. "Sakamakon Ivermectin-azithromycin-cholecalciferol hadewar jiyya akan masu cutar COVID-19: tabbacin nazarin ra'ayi." Binciken Halittu 2020; 31 (5): 129-133 Saukewa PDFTakaitacciyar: An gayyaci marasa lafiya waɗanda suka cika ka'idojin haɗawa don ɗaukar Ivermectin (6 MG sau ɗaya kowace rana a rana 0,1,7 da 8) da Azithromycin (500 MG sau ɗaya kowace rana don kwanaki 4) da Cholecalciferol (4000 UI sau biyu kowace rana don kwanaki 30). An kimanta sakamakon jiyya a ranar 10th gaba daga ranar farko na shan miyagun ƙwayoyi. Adadin farfadowa na marasa lafiya 28 da suka karɓi maganin haɗin gwiwa shine 100%, ma'anar lokacin dawo da alamun alamun shine kwanaki 3.6 kuma an tabbatar da PCR mara kyau a ranar 10. |
| 2) | Samaha Ali et al. "Sakamakon Kashi Guda na Ivermectin akan Kwayar cuta da Sakamakon asibiti a cikin Abubuwan da suka kamu da cutar SARS-CoV-2: Gwajin gwaji na asibiti a Lebanon." Kwayoyin cuta 2021 Mayu 26;13(6):989. Doi: 10.3390 / v13060989Download PDFTakaitawa: An gudanar da gwajin sarrafa bazuwar a cikin batutuwan Lebanon asymptomatic 100 waɗanda suka gwada inganci ga SARS-CoV2. Marasa lafiya 72 sun karɓi daidaitaccen magani na rigakafi, galibi kari, kuma ƙungiyar gwaji ta karɓi kashi ɗaya bisa gwargwadon nauyin ivermectin, ban da kari iri ɗaya da ƙungiyar kulawa ta samu. Sa'o'i 6 bayan an fara tsarin, haɓakar Ct-values ya fi girma a cikin ivermectin fiye da na ƙungiyar kulawa. Bugu da ƙari, ƙarin batutuwa a cikin ƙungiyar kulawa sun haɓaka alamun asibiti: mutane uku (0%) sun buƙaci asibiti, idan aka kwatanta da XNUMX% na ƙungiyar ivermectin. |
| 3) | Cadegiani, FA et al. "Farkon COVID-19 Farkon Farko tare da Azithromycin Plus Nitazoxanide, Ivermectin ko Hydroxychloroquine a cikin Saitunan Marassa lafiya An Rage Alamomin Ciki Mai Mahimmanci Idan aka kwatanta da Sanannun Sakamako a Marasa lafiya da ba a kula da su." Sabbin ƙwayoyin cuta da Sabbin cututtuka, Yuli 7, 2021. Doi: 10.1016/j.nmni.2021.100915Download PDFTakaitacciyar: Idan aka kwatanta da CG1 da CG2, AG ya nuna raguwar 31.5 zuwa 36.5% a cikin zubar da kwayar cutar hoto (p <0.0001), 70 zuwa 85% da 70 zuwa 73% a cikin tsawon lokacin bayyanar cututtuka na COVID-19 1,000), 19 daga iskar injina, da mutuwar biyar. |
| 4) | Biber A et al. "Sakamako mai kyau akan nauyin kwayar cutar hoto da ingantaccen al'ada ta amfani da Ivermectin a farkon jiyya na marasa lafiya marasa lafiya tare da COVID-19 mai laushi - makafi biyu, gwajin sarrafa wuribo bazuwar." medRxiv, Mayu 31, 2021. Doi: 10.1101/2021.05.31.21258081Download PDFTakaitacciyar: Gwajin makafi biyu idan aka kwatanta da marasa lafiya da ke karɓar ivermectin 0 · 2 mg / kg na kwanaki 3 vs. placebo a cikin marasa lafiya na COVID-19 waɗanda ba a asibiti ba… Babban ƙarshen ƙarshen shine rage ɗaukar hoto a rana ta 6 (rana ta uku bayan ƙarewar jiyya) kamar yadda aka nuna ta matakin Ct> 30 (marasa kamuwa da cuta) a cikin 6 kwana na 34) Hannun ivermectin ya kai ƙarshen ƙarshen, idan aka kwatanta da 47/72 (21%) a cikin hannun placebo… Al'adu a kwanakin 42 zuwa 50 sun kasance tabbatacce a cikin 2/6 (3%) na samfuran ivermectin vs. 23/13.0 (14%) a cikin rukunin placebo (p=29). |
| 5) | Merino J et al. "Ivermectin da rashin daidaituwa na asibiti saboda COVID-19: shaida daga binciken gwaji na gwaji dangane da sa hannun jama'a a cikin Mexico City." SocArXiv, Mayu 3, 2021. Doi: 10.31235/osf.io/r93g4Download PDFTakaitacciyar: "Mun ƙididdige ƙirar ƙididdiga-regression tare da abubuwan lura da suka dace daidai da shekaru, jima'i, tsananin COVID, da cututtuka. Mun sami raguwa mai yawa a asibitoci a tsakanin marasa lafiya waɗanda suka karɓi kayan aikin likita na tushen ivermectin; kewayon tasirin shine 52% - 76% dangane da ƙayyadaddun ƙirar. |
| 6) | Fonseca SNS et al. "Hadarin asibiti ga marasa lafiya na Covid-19 da aka bi da su tare da tsarin magunguna daban-daban a Brazil: Nazarin kwatance." Travel Med Infect Dis. 2020 Nuwamba-Disamba; 38. Doi: 10.1016/j.tmaid.2020.101906Download PDFTakaitacciyar: "Amfani da hydroxychloroquine (HCQ), prednisone ko duka biyun sun rage haɗarin asibiti da kashi 50-60% Ivermectin, azithromycin da oseltamivir ba su rage haɗarin gaba ba." |
| 7) | Lima-Morales R et al. "Ingantattun magungunan magunguna da yawa wanda ya ƙunshi Ivermectin, Azithromycin, Montelukast, da Acetylsalicylic acid don hana asibiti da mutuwa a cikin lamuran COVID-19 a cikin Tlaxcala, Mexico." Int J Infect Dis. Afrilu 2021; 105: 598-605. Doi: 10.1016/j.ijid.2021.02.014Download PDFTakaitacciyar: "An gudanar da nazarin kwatancen tasiri a tsakanin 768 da aka tabbatar da SARS-CoV-2 lokuta masu shekaru 18-80, waɗanda suka sami kulawar gaggawa… Jimlar 481 sun sami maganin TNR4, yayin da 287 suka sami wani magani (kwangiyar kwatance). Kusan 85% na lokuta waɗanda suka karɓi TNR4 sun murmure cikin kwanaki 14. Kwanaki 59 ya ninka sau 14 a cikin rukunin TNR3.4 fiye da a cikin rukunin kwatancen. |
| 8) | Loue P et al. "Ivermectin da COVID-19 a cikin Gidan Kulawa: Rahoton Case." J Kamuwa da cutar Dis Epidemiol. Afrilu 17, 2021; 7:4, 202. Doi: 10.23937 / 2474-3658 / 1510202Download PDFTakaitacciyar: "Daga cikin marasa lafiya na 25 PCR-tabbatacce, 10 sun zaɓi ɗaukar maganin IVM (ƙungiyar 1) kuma 15 sun zaɓi kada su ɗauki IVM (ƙungiyar 2). Marasa lafiya na rukunin 1 sun sami kashi ɗaya na 200 micrograms / kg nauyin jiki… Mutuwar ta faru a cikin 1 mai haƙuri a cikin rukuni na 1 da 5 (2p) = 0.34. |
| Sunan likitanci: DOXYCYCLINE |
| 1) | Hashim H et al. "Sakamakon gwajin gwaji na asibiti akan amfani da Ivermectin tare da Doxycycline don kula da marasa lafiya na COVID-19 a Baghdad, Iraki." medRxiv, Oktoba 27, 2020. Doi: 10.1101/2020.10.26.20219345Download PDFTakaitawa: Binciken da aka sarrafa bazuwar akan marasa lafiya 70 COVID-19 (48 matsakaici-matsakaici, 11 mai tsanani, da marasa lafiya 11) waɗanda aka bi da su tare da 200ug / kg PO na Ivermectin kowace rana don kwanaki 2-3 tare da 100mg PO doxycycline sau biyu a rana don kwanaki 5-10 tare da daidaitaccen magani; Hannu na biyu shine marasa lafiya 70 COVID-19 (48 masu matsakaici-matsakaici da 22 masu tsanani da marasa lafiya marasa mahimmanci) akan daidaitaccen jiyya… a tsakanin duk marasa lafiya da tsakanin marasa lafiya mai tsanani, 3/70 (4.28%) da 1/11 (9%), bi da bi sun ci gaba zuwa matakin ci gaba na cutar a cikin rukunin Ivermectin-Doxycycline tare da 7/70% (10%), bi da bi a cikin rukunin kulawa. |
| 2) | Yates P et al. "Maganin Doxycycline na babban haɗarin COVID-19-tabbatacce marasa lafiya tare da cututtukan huhu." Ci gaban warkewa a cikin Cututtukan Numfashi. Janairu 2020. Doi: 10.1177/1753466620951053Download PDFTakaitawa: Nazarin shari'a na masu haɗari huɗu masu haɗari, masu alamun COVID-19 marasa lafiya waɗanda suka nuna haɓaka cikin sauri bayan jiyya tare da doxycycline. |
| 3) | Ahmad I et al. "Doxycycline da Hydroxychloroquine a matsayin Jiyya don Babban Haɗarin Marasa lafiya COVID-19: Kwarewa daga Jerin Marasa lafiya 54 a cikin Kayan Kula da Tsawon Lokaci." medRxiv, Mayu 22, 2020. Doi: 10.1101/2020.05.18.20066902Download PDFTakaitacciyar: Jerin marasa lafiya 54 masu haɗarin gaske, waɗanda suka kamu da zazzaɓi, tari, da gajeriyar numfashi (SOB) kwatsam kuma an gano su ko ana tsammanin suna da COVID-19, an fara su tare da haɗin DOXY-HCQ da 85% (n=46) marasa lafiya sun nuna farfadowa na asibiti da aka ayyana azaman: saita zafin zazzabi da SOB, ko kuma idan marasa lafiya sun dawo. An tura jimlar 11% (n = 6) marasa lafiya zuwa asibitocin kulawa da gaggawa saboda lalacewar asibiti kuma 6% (n=3) marasa lafiya sun mutu a cikin wuraren. Kwatancen kai tsaye na Naive yana nuna waɗannan bayanan sun kasance mafi kyawun sakamako fiye da bayanan da aka ruwaito a cikin MMWR don makamantan wurare. |
| 4) | Gendrot M et al. "A cikin Vitro Antiviral Ayyukan Doxycycline akan SARS-CoV-2." Kwayoyin Halitta, 2020, 25 (21), 5064; Doi: 10.3390 / kwayoyin25215064Download PDFTakaitawa: Doxycycline ya nuna aikin in vitro akan ƙwayoyin Vero E6 da ke kamuwa da ƙwayar SARS-CoV-2 mai keɓance na asibiti (IHUMI-3) tare da matsakaicin tasiri mai tasiri (EC50) na 4.5 ± 2.9 µM, wanda ya dace da ɗaukar baki da gudanarwa na cikin jini. Doxycycline yayi hulɗa duka biyu akan shigarwar SARS-CoV-2 kuma a cikin maimaitawa bayan shigar cutar. Bayan ayyukan antiviral na in vitro a kan SARS-CoV-2, doxycycline yana da tasirin anti-mai kumburi ta hanyar rage furcin cytokines masu kumburi daban-daban kuma yana iya hana kamuwa da cuta da cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan cututtukan fata. |
| 5) | Meybodi ZA et al. "Inganci da Tsaro Doxycycline a cikin kula da marasa lafiya na COVID-19: Nazarin asibiti na matukin jirgi." Jaridar Pakistan na Kimiyyar Kiwon Lafiya da Lafiya, Yuni 2021; 15 (1): 610-614. Doi: 10.21203 / rs.3.rs-141875 / v3Download PDFTakaitacciyar: Marasa lafiya waɗanda suka cika ka'idodin haɗawa sun sami doxycycline a kashi na 100 MG kowace sa'o'i 12 na kwana bakwai sannan an kimanta su a ranar asali. A ranakun 3, 7, da 14 bayan shigar da tari, gajeriyar numfashi, zazzabi, da iskar oxygen. Binciken: A cikin marasa lafiya 21, marasa lafiya 11 maza ne, kuma marasa lafiya goma mata ne. Tari, ƙarancin numfashi, zafin jiki, da O2 sun zauna sun inganta a duka marasa lafiya da marasa lafiya idan aka kwatanta da asali. |
| Sunan likitanci: VITAMIN D |
| 1) | Kaufman H et al. "Matsakaicin ƙimar SARS-CoV-2 mai alaƙa da yawo matakan 25-hydroxyvitamin D." PLOS One, Satumba 17, 2020. Doi: 10.1371 / journal.pone.0239252Download PDFTakaitawa: Na baya-bayan nan, bincike na kallo don tantance ko zazzage matakan 25-hydroxyvitamin D (25(OH)D) suna da alaƙa da matsanancin cutar numfashi na coronavirus 2 (SARS-CoV-2). An haɗa jimlar marasa lafiya 191,779, matsakaicin shekaru 54, 68% mata. Matsakaicin ƙimar SARS-CoV-2 ya kasance mafi girma a cikin marasa lafiya 39,190 waɗanda ke da ƙimar “rashi” 25 (OH) D (<20 ng/mL) (12.5%, 95% CI 12.2 – 12.8%) fiye da a cikin marasa lafiya 27,870 tare da “isasshen” ƙimar (30/34% CI) (8.1% 95) 7.8-8.4%) da marasa lafiya na 12,321 tare da ƙimar ≥55 ng/mL (5.9%, 95% CI 5.5-6.4%). |
| 2) | Isra'ila A et al. "Haɗin da ke tsakanin rashi bitamin D da Covid-19 a cikin yawan jama'a." medRxiv, Satumba 7, 2020. Doi: 10.1101/2020.09.04.20188268Download PDFTakaitawa: Nazarin tushen yawan jama'a don tantance alaƙa tsakanin yawaitar rashi bitamin D da abin da ya faru na COVID-19. An daidaita majinyata 52,405 da suka kamu da cutar tare da mutane 524,050 masu iko na jinsi ɗaya, shekaru, yanki na yanki kuma sun yi amfani da koma bayan dabaru na yanayi don tantance alakar da ke tsakanin matakan bitamin D na asali, samun ƙarin bitamin D a cikin watanni 4 da suka gabata, da tabbataccen COVID-19. An sami alaƙa mai ma'ana sosai tsakanin yawaitar rashi bitamin D da abin da ya faru na COVID-19, da kuma tsakanin rabon mace-da-namiji don tsananin ƙarancin bitamin D da rabon mace-da-namiji don cutar COVID-19. A cikin ƙungiyar da ta dace, an sami alaƙa mai mahimmanci tsakanin ƙarancin matakan bitamin D da haɗarin COVID-19, tare da mafi girman haɗarin da aka gani don ƙarancin ƙarancin bitamin D. An lura da babban tasiri na kariya ga membobin da suka sami tsarin bitamin D na ruwa (digo) a cikin watanni 4 na ƙarshe. |
| 3) | Katz J. "Ƙara haɗari ga COVID-19 a cikin marasa lafiya da rashin bitamin D." Gina Jiki, 2021 Afrilu; 84: 111106. Doi: 10.1016 / j.nut.2020.111106Download PDFTakaitawa: Marasa lafiya da ke da rashi bitamin D sun kasance sau 4.6 mafi kusantar zama tabbatacce ga COVID-19 (wanda aka nuna ta lambar gwajin ICD-10 COVID19) fiye da marasa lafiya da ba su da rashi (P <0.001). Bugu da ƙari, marasa lafiya da ke da rashi bitamin D sun kasance sau 5 mafi kusantar kamuwa da COVID-19 fiye da marasa lafiya da ba su da rashi bayan daidaitawa don ƙungiyoyin shekaru (OR = 5.155; P <0.001). |
| 4) | Baktash V et al. "Matsayin Vitamin D da sakamako ga tsofaffi marasa lafiya da ke da COVID-19." Postgrad Med J. 2021 Jul;97(1149):442-447. Doi: 10.1136/postgradmedj-2020-138712Download PDFTakaitawa: Nazarin ƙungiyar masu zuwa tsakanin 1 ga Maris da 30 ga Afrilu 2020 don tantance mahimmancin rashi na bitamin D a cikin tsofaffin marasa lafiya da COVID-19. Ƙungiyar ta ƙunshi marasa lafiya masu shekaru ≥65 masu gabatar da alamun da suka yi daidai da COVID-19 (n=105). Hannun-tabbatacce COVID-19 ya nuna ƙananan matsakaicin jini 25 (OH) D matakin 27 nmol/L (IQR=20-47 nmol/L) idan aka kwatanta da COVID-19-korau hannu, tare da matsakaicin matakin 52 nmol/L (IQR=31.5-71.5 nmol/L) (kimanci 0.0008). Daga cikin marasa lafiya da raunin bitamin D, akwai matakin D-dimer mafi girma (1914.00 μgFEU/L vs 1268.00 μgFEU/L) (p=0.034) da mafi girma na goyon bayan NIV da shigar da sashin dogara mai girma (30.77% vs 9.68%) (p=0.042) |
| 5) | Martín Giménez VM et al. "Rashin bitamin D a Amurkawa na Afirka yana da alaƙa da babban haɗarin cuta mai tsanani da mace-mace ta SARS-CoV-2." Mujallar hawan jini juzu'i na 35, shafi na 378-380 (2021). Doi: 10.1038 / s41371-020-00398-zDownload PDFTakaitacciyar: Duk da rashin nazarin don ayyana isasshen matakin bitamin D don kare kariya daga kamuwa da cuta, mun yarda da Grant et al., Kuma an kiyasta cewa kewayon tsakanin 40 da 60 mg / dL da shawarar da aka ba da shawarar don cimma wannan, tsakanin 5000 da 10,000 IU / rana don makonni da yawa. |
| 6) | Ricci A et al. "Matsakaicin matakan Vitamin D da ke yawo da kuma alamun hasashen asibiti a cikin marasa lafiya na COVID-19." Binciken Numfashi juzu'i na 22, lambar labarin: 76 (2021). Doi: 10.1186/s12931-021-01666-3Download PDFTakaitawa: Matakan Vitamin D sun yi karanci a cikin (80%) na marasa lafiya, rashin isa (6.5%) da kuma na yau da kullun (13.5%). Marasa lafiya waɗanda ke da ƙananan matakan plasma na Vitamin D suna da ƙimar D-Dimer mafi girma, ƙimar ƙwayoyin lymphocyte B mafi girma, raguwar CD8 + T lymphocytes tare da ƙarancin CD4/CD8, ƙarin binciken binciken asibiti (wanda aka auna ta LIPI da maki SOFA) da kuma shigar da CT scan na thoracic. Karancin bitamin D yana da alaƙa da haɓakar martanin kumburin kumburi da haɓakar huhu a cikin majinyatan COVID-19 da abin ya shafa. |
| 7) | Lakkireddy M et al. "Tasirin babban maganin maganin bitamin D na yau da kullun akan alamun kumburi a cikin marasa lafiya da ke da cutar COVID 19." Rahoton Kimiyya vol 11, Mayu 20, 2021. Doi: 10.1038/s41598-021-90189-4Download PDFTakaitawa: Inganta maganin warkewa a cikin bitamin D zuwa 80-100 ng/ml ya rage mahimmancin alamun kumburin da ke hade da COVID-19 ba tare da wani tasiri ba. |
| Sunan likitanci: Tutiya |
| 1) | Carlucci P et al. "Zinc sulfate a hade tare da zinc ionophore na iya inganta sakamako a cikin marasa lafiya na COVID-19." Jaridar Medical Microbiology, Satumba 15, 2020, v 69 fitowar 10. Doi: 1099/jmm.0.001250Download PDFTakaitawa: A cikin nazari na univariate, zinc sulphate ya kara yawan adadin marasa lafiya da ake sallama a gida, kuma ya rage buƙatar samun iska, shigar da ICU da mace-mace ko canja wuri zuwa asibiti ga marasa lafiya waɗanda ba a taɓa shigar da su a cikin ICU ba. |
| 2) | Dubourg G et al. "Rashin ƙwayar zinc na jini a cikin marasa lafiya da ke da mummunan sakamako na asibiti yayin kamuwa da cuta ta SARS-CoV-2: shin akwai buƙatar ƙarawa da marasa lafiyar zinc COVID-19?" Jaridar Microbiology, Immunology da Kamuwa da cuta, Fabrairu 13, 2021. 1016/j.jmii.2021.01.012Download PDFTakaitacciyar: Daga cikin marasa lafiya 275 da ke da COVID-19, mun gano cewa matakin zinc na tsakiya ya ragu sosai a cikin marasa lafiya tare da mummunan sakamako na asibiti (N=75) idan aka kwatanta da marasa lafiya da ke da kyakkyawan sakamako na asibiti (N=200) (840 μg/L da 970 μg/L; p<0.0001), yana ba da shawarar cewa kariyar zinc19 na iya zama mai amfani ga masu cutar COVID-XNUMX. |
| 3) | Frontera J et al. "Jiyya tare da Zinc yana Haɗe da Rage Mutuwar Asibiti Tsakanin Marasa lafiya na COVID-19: Nazarin Ƙwararrun Ƙwararrun Ƙungiyoyi." BMC Cututtuka masu Yaduwa [preprint]. Oktoba 26, 2020. Doi: 21203 / rs.3.rs-94509 / v1Download PDFTakaitawa: Daga cikin marasa lafiya 3,473 (tsakiyar shekaru 64, 1947 [56%) maza, 522 [15%] sun sami iska, 545 [16%] sun mutu), 1,006 (29%) sun karɓi Zn + ionophore. Zn+ionophore yana da alaƙa da raguwar 24% na haɗarin mace-mace a asibiti (12% na waɗanda suka karɓi Zn+ionophore sun mutu akan 17% waɗanda basu yi ba). |
| 4) | Heller RA et al. "Hasashen rashin daidaituwar rayuwa a cikin COVID-19 ta zinc, shekaru da selenoprotein P a matsayin mai hadewar halittu." Redox Biology, Janairu 2021, v 38. Doi: 1016/j.redox.2020.101764Download PDFTakaitawa: Bayananmu sun nuna babban rashi na zinc a yawancin marasa lafiya da COVID-19 lokacin da aka shigar da su asibiti. … Mun kammala cewa matsayin Zn da SELENOP a cikin jeri na nuni suna nuna babban rashin daidaituwar rayuwa a cikin COVID-19, kuma muna ɗauka cewa gyara ƙarancin da aka tabbatar a cikin Se da/ko Zn ta hanyar keɓaɓɓen kari na iya tallafawa jin daɗi. |
| 5) | Vogel-González M et al. "Ƙananan matakan zinc a cikin haɗin gwiwa na asibiti tare da sakamako mara kyau a cikin COVID-19." medRxiv, Oktoba 11, 2020. Doi: 1101/2020.10.07.20208645Download PDFTakaitacciyar: Mutanen da ke da SZC a shigar da <50 µg/dl suna da mace-mace na 21% wanda ya fi girma idan aka kwatanta da 5% mace-mace a cikin mutane tare da zinc a shigar ≥50 µg/dl; p<0·001. Bincikenmu yana nuna alaƙa tsakanin matakan zinc na jini da sakamakon COVID-19. Matakan zinc da ke ƙasa da 50 mcgg/dl yayin shigar da su yana da alaƙa da mafi munin gabatarwar asibiti, tsayin lokaci don samun kwanciyar hankali da haɓaka mace-mace. |
| 6) | Jothimani D et al. "COVID-19: Sakamako mara kyau a cikin marasa lafiya da karancin zinc." Jaridar Duniya ta Cututtukan Kamuwa, Nuwamba 2020, v 100: 343-349. Doi: 1016/j.ijid.2020.09.014Download PDFTakaitawa: Ƙarin marasa lafiya a cikin rukunin ƙarancin Zinc… suna buƙatar kulawar ICU (7 vs 2, P=0.266) da mutuwar da aka rubuta (5 vs 0) idan aka kwatanta da marasa lafiya tare da matakan Zinc na yau da kullun. |
| 7) | Yasui Y et al. "Binciken abubuwan tsinkaya don rashin lafiya mai tsanani na COVID-19 yayin jiyya - dangantaka tsakanin matakin zinc da rashin lafiya na COVID-19." Jaridar Duniya na Cututtuka masu Yaduwa, Nuwamba 2020, v 100: 230-236. Doi: 1016/j.ijid.2020.09.008Download PDFTakaitawa: Dangane da sakamakon auna ma'aunin sinadarin zinc a cikin marasa lafiya da ke da COVID-19 a cikin asibitinmu, kusan dukkanin lokuta masu tsanani sun nuna raunin zinc na asibiti ko na asibiti. An gano tsawan hypozincemia a matsayin haɗarin haɗari ga mummunan yanayin COVID-19. A cikin kimanta alaƙar da ke tsakanin matakin zinc ɗin jini da tsananin marasa lafiya tare da COVID-19 ta hanyar bincike mai zurfi na rikice-rikice masu yawa, ana iya annabta rashin lafiya ta hanyar hankali da ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙayyadaddun ROC tare da ƙimar kuskure na 10.3% da AUC na 94.2% ta dalilai biyu kawai: darajar serum (P = 0.020) da ƙimar zinc. |
| 8) | Derwand R et al. "Masu lafiya na COVID-19: farkon haɗarin-masu haɗari tare da zinc tare da ƙaramin adadin hydroxychloroquine da azithromycin: nazarin jerin shari'o'i." Jarida ta Ƙasashen Duniya na Ma'aikatan Kwayoyin cuta, Disamba 2020, v 56:6. Doi: 1016/j.ijantimicag.2020.106214Download PDFTakaitacciyar: Bayan kwanaki 4 (matsakaici, IQR 3-6, akwai don N = 66/141) na farkon bayyanar cututtuka, marasa lafiya 141 (tsakanin shekaru 58, IQR 40-67; 73% namiji) sun sami takardar sayan magani don maganin sau uku na kwanaki 5. Bayanai masu zaman kansu na jama'a daga 377 sun tabbatar da cewa an yi amfani da marasa lafiyar COVID-19 na al'umma ɗaya azaman kulawar da ba a kula da su ba. 4 na 141 da aka bi da marasa lafiya (2.8%) an kwantar da su a asibiti, wanda ya kasance ƙasa da ƙasa (p<0.001) idan aka kwatanta da 58 na 377 marasa lafiya (15.4%) (rabo 0.16, 95% CI 0.06-0.5). Ɗaya daga cikin marasa lafiya (0.7%) ya mutu a cikin rukunin jiyya tare da marasa lafiya 13 (3.5%) a cikin ƙungiyar da ba a kula da su ba (rabo 0.2, 95% CI 0.03-1.5; p = 0.12). |
| Sunan likitanci: COLCHICINE |
| 1) | Tardif JC et al. "Colchicine ga marasa lafiya da ke kula da al'umma tare da COVID-19 (COLCORONA): lokaci na 3, bazuwar, makafi biyu, daidaitawa, sarrafa wuribo, gwaji na tsakiya." Lancet Respira Med. 2021 Mayu 27; Doi: 10.1016/S2213-2600(21)00222-8Download PDFTakaitacciyar: An ba da marasa lafiya 2,235 bazuwar zuwa colchicine da 2,253 zuwa placebo. Daga cikin marasa lafiya da PCR-tabbatar da COVID-19, colchicine ya haifar da ƙarancin adadin adadin mutuwa ko shigar da asibiti fiye da placebo. |
| 2) | Scarsi M et al. "Haɗin kai tsakanin jiyya tare da colchicine da ingantacciyar rayuwa a cikin rukunin cibiyar guda ɗaya na manya marasa lafiya da ke asibiti tare da COVID-19 ciwon huhu da kuma matsanancin ciwon numfashi." Ann Rheum Dis. Oktoba 2020; 79 (10): 1286-1289. Doi: 10.1136/annrheumdis-2020-217712Download PDFTakaitaccen bayani: An yi wa marasa lafiya 140 a jere tare da daidaitattun kulawa (hydroxychloroquine da/ko dexamethasone na ciki; da/ko lopinavir/ritonavir). An kwatanta su da marasa lafiya na 122 a jere da aka bi da su tare da colchicine da daidaitattun kulawa (an dakatar da magungunan rigakafi kafin colchicine, saboda yiwuwar hulɗar). Marasa lafiya da aka bi da colchicine sun sami mafi kyawun rayuwa idan aka kwatanta da SoC a kwanakin 21 na biyo baya (84.2% vs 63.6%). |
| Sunan likitanci: Farashin BROMHEXINE |
| 1) | Ansarin et al. "Tasirin bromhexine akan sakamakon asibiti da mace-mace a cikin marasa lafiya na COVID-19: Gwajin asibiti bazuwar." BioImpacts, 2020, 10 (4), 209-215. Doi: 10.34172/bi.2021.30Download PDFTakaitawa: Jimillar marasa lafiya 78 da ke da irin wannan alƙaluma da halaye na cuta an yi rajista. An sami raguwa mai yawa a cikin shigar da ICU (2 daga 39 vs. 11 daga 39, P = 0.006), intubation (1 daga 39 vs. 9 daga 39, P = 0.007) da mutuwa (0 vs. 5, P = 0.027) a cikin ƙungiyar da aka bi da bromhexine idan aka kwatanta da daidaitattun rukuni. Babu marasa lafiya da aka janye daga binciken saboda mummunan tasiri. |
| 2) | Li et al. "Bromhexine Hydrochloride Allunan don Kula da Matsakaicin COVID-19: Buɗe Label Nazartar Matukin Jirgin Sama." Clin. Fassarar Sci (2020) 13, 1096-1102. Doi: 10.1111/ct.12881Download PDFTakaitawa: Jimlar marasa lafiya 18 masu matsakaicin COVID-19 an bazu cikin ƙungiyar BRH (n = 12) ko ƙungiyar kulawa (n = 6). Akwai shawarwarin fa'idar BRH akan placebo a cikin ingantaccen ƙirjin ƙirji, buƙatar maganin iskar oxygen, da yawan fitarwa a cikin kwanaki 20. |
| 3) | Maggio et al. "Sake dawo da maganin tari na mucolytic da TMPRSS2 protease inhibitor bromhexine don rigakafi da sarrafa kamuwa da cutar SARS-CoV-2." Binciken Pharmacological 157 (Yuli 2020) 104837 Doi: 10.1016/j.phrs.2020.104837Takaitawa: Bayanan Pharmacokinetic sun goyi bayan gwajin amfani da bromhexine don wannan alamar tun lokacin da, a cikin huhu da kuma ƙwayoyin epithelial na huhu, zai iya kaiwa 4 zuwa 6-ninka fiye da waɗanda aka samu a cikin plasma, babban isa bisa manufa don hana TMPRSS2. |
| 4) | Mareev, et al. "Sakamakon buɗe ido, mai yiwuwa, sarrafawa, nazarin kwatance don maganin kamuwa da cutar coronavirus (COVID-19): Bromhexine
Kuma Spironolactone don kula da Cutar Kwayar cuta ta Corona da ke buƙatar Asibiti (BISQUIT)." Kardiologiia, 2020; 60 (11). 10.18087 / cardio.2020.11.n1440Fassarar Ingilishi: https://pubmed.ncbi.nlm.nih.gov/33487145/Download PDFTakaitacciyar: An haɗa marasa lafiya 103 (33 a cikin ƙungiyar bromhexine da spironolactone da 70 a cikin ƙungiyar kulawa). Bincike ga ƙungiyar gaba ɗaya ya nuna raguwar ƙididdiga a lokacin asibiti daga kwanaki 10.4 zuwa 9.0 da lokacin zazzabi daga kwanaki 6.5 zuwa 3.9. |
| 5) | Mikhaylov, et al. "Bromhexine Hydrochloride Prophylaxis na COVID-19 don Ma'aikatan Kiwon Lafiya: Nazarin Buɗe Label Randomized." medRxiv preprint, Mayu 29, 2021. Doi: 10.1101/2021.03.03.21252855Download PDFTakaitawa: An sanya ma'aikatan kiwon lafiya 25 zuwa maganin bromhexine hydrochloride (8 MG sau 3 a rana), kuma 25 sun kasance masu sarrafawa. Ƙananan mahalarta sun sami alamun COVID-19 a cikin rukunin jiyya idan aka kwatanta da sarrafawa (0/25 vs 5/25). |
| 6) | Ku, et al. "TmPRSS2 ne ke rage hanawar shigawar SARS-CoV-2 na Hydroxychloroquine." PLOS Pathogens, Janairu 19, 2021. Doi: 10.1371/jarida.ppat.1009212Download PDF (daga gidan yanar gizon PLOS) Takaitawa: Mun nuna cewa haɗuwar hydroxychloroquine da mai hana TMPRSS2 da aka gwada ta asibiti suna aiki tare don hana shigar SARS-CoV-2 yadda ya kamata. |
| Sunan likitanci: BUDESONIDE |
| 1) | Ramakrishnan S et al. "Budesonide inhaled a farkon COVID-19 (STOIC): lokaci na 2, buɗaɗɗen lakabin, gwajin sarrafawa bazuwar." Lancet Respira Med, Afrilu 9, 2021. Doi: 10.1016/ S2213-2600(21)00171-5Download PDFTakaitacciyar: An ba da mahalarta 146 bazuwar, 73 zuwa kulawa na yau da kullun da 73 zuwa budesonide. Ga kowace ƙa'ida (n=139), sakamako na farko ya faru a cikin goma (14%) na mahalarta 70 a cikin rukunin kulawa da aka saba da ɗaya (1%) na mahalarta 69 a cikin rukunin budesonide. Ga yawan jama'ar ITT, sakamakon farko ya faru a cikin 11 (15%) mahalarta a cikin ƙungiyar kulawa ta yau da kullum da kuma biyu (3%) mahalarta a cikin ƙungiyar budesonide. Farfadowa na asibiti ya kasance kwana 1 gajarta a cikin rukunin budesonide idan aka kwatanta da rukunin kulawa da aka saba (tsakiyar kwanaki 7 da 8). Matsakaicin adadin kwanaki tare da zazzaɓi a cikin kwanaki 14 na farko ya kasance ƙasa a cikin rukunin budesonide fiye da rukunin kulawa na yau da kullun (2% da 8%) kuma adadin mahalarta tare da aƙalla kwana 1 na zazzabi ya ragu a cikin rukunin budesonide idan aka kwatanta da ƙungiyar kulawa ta yau da kullun. Ƙananan mahalarta waɗanda aka ba da izini ga budesonide suna da alamun bayyanar cututtuka a kwanaki 14 da 28. |
| Sunan likitanci: DEXAMETHASONE |
| 1) | Tomazini BM et al. "Tasirin Dexamethasone akan Ranaku Masu Rayuwa da Kyautar iska a cikin Marasa lafiya masu matsakaicin matsakaici ko matsananciyar Ciwon Ciwon Hankali da COVID-19CoDEX Randomized Clinical Trial." JAMA, Satumba 2, 2020. Doi: 10.1001/jama.2020.17021Download PDFTakaitacciyar: A cikin wannan gwaji na asibiti da aka bazu wanda ya haɗa da marasa lafiya 299, adadin kwanakin da suke raye kuma ba su da isasshen iska a cikin kwanaki 28 na farko sun yi girma sosai a tsakanin marasa lafiya da aka yi musu magani tare da dexamethasone tare da daidaitaccen kulawa idan aka kwatanta da daidaitaccen kulawa kadai (kwanaki 6.6 vs 4.0 kwanaki). |
| 2) | Horby P et al. (Madogara Haɗin gwiwa). "Dexamethasone a cikin marasa lafiya da ke da COVID-19." NEJM, Fabrairu 25, 2021. Doi: 10.1056 / NEJMOA2021436Download PDFTakaitacciyar: A cikin marasa lafiya da ke asibiti tare da Covid-19, amfani da dexamethasone ya haifar da raguwar mace-mace na kwanaki 28 a tsakanin waɗanda ke karɓar ko dai iskar iska ta iska ko iskar oxygen kaɗai a cikin bazuwar amma ba cikin waɗanda ke samun tallafin numfashi ba. |
| Sunan likitanci: MAGANGANUN GASKIYA |
| 1) | Verderese JP et al. "Maganin Jiyya na Monoclonal Antibody Neutralizing Yana Rage Asibiti don Cutar Coronavirus Mai Sauƙi da Matsakaici 2019 (COVID-19): Kwarewar Duniya ta Gaskiya." Cutar cututtuka na asibiti, Yuni 24, 2021. Doi: 10.1093/cid/ciab579Download PDFTakaitawa: 707 da aka tabbatar da COVID-19 marasa lafiya sun karɓi NmAbs kuma an haɗa abubuwan sarrafa COVID-1709 na tarihi guda 19; 553 (78%) sun sami BAM, 154 (22%) sun sami REGN-COV2. Marasa lafiya da ke karɓar jiko na NmAb suna da ƙananan ƙimar asibiti (5.8% vs 11.4%, P <.0001), ɗan gajeren lokaci na zama idan an kwantar da shi (ma'ana, 5.2 vs 7.4 days; P = .02), da ƙarancin ED a cikin kwanaki 30 bayan-index (8.1% vs 12.3%, P) fiye da sarrafawa. |
| 2) | O'Brien MP et al. "Haɗin rigakafin REGEN-COV na Subcutaneous don Hana Covid-19." NEJM, Agusta 4, 2021. Doi: 10.1056 / NEJMOA2109682Download PDFTakaitawa: Alamun kamuwa da cutar SARS-CoV-2 da aka haɓaka a cikin 11 na mahalarta 753 a cikin ƙungiyar REGEN-COV (1.5%) kuma a cikin 59 na mahalarta 752 a cikin rukunin placebo (7.8%) (rage haɗarin dangi [1 ban da haɗarin dangi], 81.4%; P <0.001). A cikin makonni 2 zuwa 4, jimlar 2 na mahalarta 753 a cikin rukunin REGEN-COV (0.3%) da 27 na mahalarta 752 a cikin rukunin placebo (3.6%) suna da alamun kamuwa da cutar SARS-CoV-2 (raguwar haɗari, 92.6%). REGEN-COV kuma ya hana bayyanar cututtuka da cututtukan asymptomatic gabaɗaya (raguwar haɗari, 66.4%). Daga cikin mahalarta masu kamuwa da alamun bayyanar cututtuka, matsakaicin lokacin don magance alamun ya kasance makonni 2 ya fi guntu tare da REGEN-COV fiye da placebo (makonni 1.2 da makonni 3.2, bi da bi), kuma tsawon lokacin babban nauyin hoto (> kwafin 104 a kowace millilita) ya fi guntu (makonni 0.4 da makonni 1.3, bi da bi). Ba a lura da tasirin-iyakan guba na REGEN-COV ba. |
| Sunan likitanci: QUERCETIN |
| 1) | Di Pierro F et al. "Mai yiwuwa Tasirin warkewa na Adjuvant Quercetin Supplement Again Farko COVID-19 kamuwa da cuta: mai yiwuwa, Bazuwar, Sarrafa, da Budaddiyar Label." Int J General Med, Yuni 8, 2021. Doi: 10.2147/IJGM.S318720Download PDFTakaitawa: Mai yiwuwa, bazuwar, sarrafawa, da binciken buɗaɗɗen lakabi. An bincika kashi na yau da kullun na 1000 MG na QP na kwanaki 30 a cikin 152 COVID-19 marasa lafiya don bayyana tasirin sa a cikin magance alamun farko da kuma hana mummunan sakamakon cutar. Sakamakon ya nuna raguwa a cikin mita da kuma tsawon asibiti, da buƙatar maganin iskar oxygen mara kyau, ci gaba zuwa sassan kulawa mai tsanani da kuma yawan mutuwar. Sakamakon ya kuma tabbatar da ingancin lafiyar quercetin. |
| Sunan likitanci: FLUVOXAMIN |
| 1) | Lenze E et al. "Fluvoxamine vs Placebo da lalacewar asibiti a cikin marasa lafiya tare da Alamun COVID-19. Gwajin Nazari na asibiti." JAMA. 2020; 324 (22): 2292-2300. Doi: 10.1001 / jama.2020.22760Takaitawa: A cikin wannan gwajin bazuwar wanda ya haɗa da majinyata manya guda 152 waɗanda aka tabbatar da COVID-19 da alamun bayyanar a cikin kwanaki 7, tabarbarewar asibiti ta faru a cikin marasa lafiya 0 da aka yi musu magani tare da fluvoxamine vs 6 (8.3%) marasa lafiya da aka yi musu magani tare da placebo sama da kwanaki 15, bambancin da ke da mahimmancin ƙididdiga. |
| 2) | Reis G et al. "Tasirin jiyya da wuri tare da fluvoxamine akan haɗarin kulawar gaggawa da asibiti a tsakanin marasa lafiya tare da COVID-19: TARE da bazuwar, gwajin asibiti." Lancet Global Health. Oktoba 27, 2021; 10 (1): E42-E51. Doi: 10.1016/S2214-109X(21)00448-4Takaitawa: Adadin marasa lafiya da aka lura a cikin yanayin gaggawa na COVID-19 na sama da 6 h ko kuma an tura su zuwa asibiti na wucin gadi saboda COVID-19 ya ragu ga rukunin fluvoxamine idan aka kwatanta da placebo (79 [11%] na 741 vs 119 [16%] na 756) [. . .] Akwai mutuwar 17 a cikin rukuni na fluvoxamine da 25 mutuwar a cikin rukunin placebo a cikin farkon niyya don maganin bincike (rashin daidaituwa [OR] 0 · 68, 95% CI: 0 · 36-1 · 27). Akwai mutuwa guda ɗaya a cikin ƙungiyar fluvoxamine da 12 a cikin rukunin placebo don yawan ka'ida (OR 0 · 09; 95% CI 0 · 01-0 · 47). |
| 3) | Seftel D et al. "Ƙungiyar Fluvoxamine mai yiwuwa don Maganin Farko na Cutar Coronavirus 19." Bude Dandalin Cututtuka masu Yaduwa, juzu'i na 8, fitowa ta 2, Fabrairu 2021. Doi: 10.1093/ofid/ofab050Download PDFTakaitawa: Abubuwan da suka faru na asibiti shine 0% (0 na 65) tare da fluvoxamine da 12.5% (6 na 48) tare da lura kadai. A cikin kwanaki 14, sauran alamun bayyanar sun ci gaba a cikin 0% (0 na 65) tare da fluvoxamine da 60% (29 na 48) tare da lura. |
| Therapeutic sunan: PREDNISONE |
| 1) | Ooi ST et al. "Antivirals Tare da Adjunctive Corticosteroids Hana Ci gaban Clinical na Farkon Coronavirus 2019 Pneumonia: Nazarin Haɗin Kai." Bude Dandalin Balaguro Cututtuka, Juzu'i na 7, fitowar 11, Nuwamba 2020, ofaa486. Doi: 10.1093/ofid/ofaa486Download PDFTakaitawa: "Haɗin corticosteroids da antivirals yana da alaƙa da ƙananan haɗarin ci gaba na asibiti da iska mai cutarwa ko mutuwa a farkon cutar huhu ta COVID-19." |
| 2) | Fonseca SNS et al. "Hadarin asibiti ga marasa lafiya na Covid-19 da aka bi da su tare da tsarin magunguna daban-daban a Brazil: Nazarin kwatance." Travel Med Infect Dis. 2020 Nuwamba-Disamba; 38. Doi: 10.1016/j.tmaid.2020.101906Download PDFTakaitawa: "Amfani da hydroxychloroquine (HCQ), prednisone ko duka biyun sun rage haɗarin asibiti da kashi 50-60%." |
| Sunan likitanci: AZITHROMYCIN |
| 1) | Taieb F et al. "Maganin Hydroxychloroquine da Azithromycin na Marasa lafiyar Asibiti da suka kamu da SARS-CoV-2 a Senegal daga Maris zuwa Oktoba 2020." J Clin Med, 2021 Juni 30;10 (13):2954. Doi: 3390 / jcm10132954.Download PDFTakaitawa: An haɗa jimillar marasa lafiya 926 a cikin wannan bincike. Dari shida da saba'in da hudu (674) (72.8%) marasa lafiya sun sami hadewar HCQ da AZM. Sakamako ya nuna cewa yawan fitarwar marasa lafiya a D15 ya fi girma ga marasa lafiya da ke karɓar HCQ da AZM (OR: 1.63, IC 95% (1.09-2.43). |
| 2) | Lagier JC et al. "Sakamako na 2,111 COVID-19 marasa lafiya da ke kwance a asibiti da aka yi musu magani tare da hydroxychloroquine/azithromycin da sauran tsarin mulki a Marseille, Faransa: nazari na baya-bayan nan." IHU-Méditerranée Infection [preprint], Yuni 4, 2021.Download PDFTakaitawa: Jiyya tare da HCQ-AZ wani abu ne mai zaman kansa na kariya daga mutuwa - Zinc yana kare kansa daga mutuwa a cikin marasa lafiya da aka yi wa HCQ-AZ. |
| 3) | Heras E et al. " Abubuwan haɗarin mace-mace na COVID-19 a cikin tsofaffi a cikin cibiyar kulawa ta dogon lokaci." Magungunan Geriatric na Turai, Nuwamba 27, 2020, v 12, p 601-607. Doi: 1007 / s41999-020-00432-wDownload PDFTakaitawa: Daga cikin 100 COVID-19+ marasa lafiya na gida a Andorra, bincike-bincike na logistics bincike ya gano hydroxychloroquine tare da azithromycin a matsayin wani abu mai zaman kansa wanda ke fifita rayuwa idan aka kwatanta da babu magani ko wasu jiyya. |
| 4) | Ly TDA et al. "Tsarin kamuwa da cutar SARS-CoV-2 tsakanin tsofaffi mazauna mazaunin da ke zaune a wuraren kulawa na dogon lokaci a Marseille, Faransa, Maris-Yuni 2020." Int J Antimicrob Agents, 2020 Dec;56(6):106219. Doi: 1016/j.ijantimicag.2020.106219Takaitawa: An tattara bayanai daga tsofaffi mazauna 1,691 da membobin ma'aikata 1,000 ta hanyar yin hira da ƙungiyoyin likitocin a cikin 24 LTCFs da kuma amfani da tsarin rikodin lafiya na lantarki na asibitoci. 116 (51.4%) marasa lafiya sun sami hanyar maganin hydroxychloroquine na baka da azithromycin (HCQAZM) na ≥3 kwanaki, kuma 47 (20.8%) sun mutu. Ta hanyar bincike mai yawa, yawan mutuwar yana da dangantaka da kasancewa namiji (30.7%, vs. 14.0%, OR = 3.95, p=0.002), kasancewa fiye da shekaru 85 (26.1%, vs. 15.6%, OR = 2.43, p=0.041), da kuma karbar maganin oxygen, OR = 39.0. p <12.9) da kuma mummunan dangantaka da ana gano su ta hanyar nazarin taro (5.16%, vs. 0.001%, OR = 16.9, p=40.5) da kuma karbar maganin HCQ-AZM ≥0.20 kwanaki (0.001%, vs. 3%, OR=15.5, p=26.4) |
| 5) | Lauriola M et al. "Tasirin haɗin maganin hydroxychloroquine da azithromycin akan mace-mace a cikin marasa lafiya na COVID-19." Clinical da Kimiyyar Fassara, Satumba 14, 2020. Doi: 1111/ct.12860Download PDFTakaitawa: A cikin wannan binciken, mun sami raguwar mace-mace a asibiti a cikin marasa lafiya da aka yi amfani da su tare da haɗin hydroxychloroquine da azithromycin bayan daidaitawa don kamuwa da cuta. A multivariable Cox proportional hazard analysis, … amfani da hydroxychloroquine + azithromycin (ba tare da jiyya ba) (HR 0.265, 95% CI 0.171-0.412, p<0.001) yana da alaƙa da alaƙa da mutuwa. |
| 6) | Arshad S et al. "Maganin Hydroxychloroquine, Azithromycin, da Haɗuwa a cikin Marasa lafiya da ke Asibiti tare da COVID-19." Int Jour Inf Dis, Yuli 1, 2020, 97: 396-403. Doi: 10.1016/j.ijid.2020.06.099Download PDFTakaitawa: A cikin wannan kima na asibiti da yawa, lokacin da ake sarrafa abubuwan haɗari na COVID-19, jiyya tare da hydroxychloroquine kadai kuma a hade tare da azithromycin yana da alaƙa da raguwa a cikin mace-mace masu alaƙa da COVID-19. |
| Sunan likitanci: HIDROXYCHLOROQUINE (Hoto 2) |
| 1) | Rish, Harvey. "Hydroxychloroquine a Farko na Jiyya na Babban Haɗari na COVID-19 Marasa lafiya: Ingantawa da Shaidar Tsaro." Sigar ta shida, sabunta Yuni 17, 2021. Zazzagewa PDFTakaitawa: Kowane binciken da aka yi na amfani da majinyata mai haɗari na hydroxychloroquine (HCQ) ya nuna raguwar haɗarin asibiti ko mace-mace. Meta-bincike yana nuna raguwar 40% a asibiti da raguwar 75% a mace-mace. Wani babban binciken bayanai na tsofaffin marasa lafiya sama da 900,000 da ke shan hydroxychloroquine bai nuna yawan mace-mace ba kuma babu wuce gona da iri na cututtukan zuciya na zuciya. |
| 2) | Million M et al. "Maganin farko tare da hydroxychloroquine da azithromycin a cikin marasa lafiya 10,429 na COVID-19: Nazarin rukuni na baya-bayan nan." An karɓa don bugawa, Int J Infect Dis.Download PDFTakaitawa: Ƙungiyar 10,429 COVID-19 marasa lafiya da aka yi wa HCQ, azithromycin da sauran magunguna. A cikin marasa lafiya masu shekaru 60 zuwa sama, 1,495 marasa lafiya da aka yi wa HCQ+azithromycin na tsawon kwanaki 3+ an kwatanta su da marasa lafiya 520 da aka ba su magungunan kasa da kwanaki 3, ko kuma an ba su magungunan guda ɗaya kawai, ko kuma ba a ba su ko ɗaya ba. Shekaru, jima'i da lokacin-lokaci-lokaci-lokacin daidaita-bincike-bincike ya nuna rashin daidaituwar mace-mace na 0.17. |
| 3) | Mokhtari M et al. "Sakamakon asibiti na marasa lafiya tare da COVID-19 mai sauƙi biyo bayan jiyya tare da hydroxychloroquine a cikin wurin jinya. Int Immunopharmacol Vol 96, Yuli 2021. Doi: 10.1016/j.intimp.2021.107636Download PDFTakaitawa: Multi-center, binciken ƙungiyar ƙasa da ƙasa na yawan mutane 28,759 tare da COVID-19 mai sauƙi da aka gani a cikin kwanaki 7 na bayyanar cututtuka tsakanin Maris da Satumba 2020 a Iran. Jiyya tare da HCQ yana da alaƙa da raguwar 38% cikin haɗarin asibiti da raguwar 70% a cikin haɗarin mace-mace, duka biyun suna da mahimmancin ƙididdiga. |
| 4) | Barbosa Esper, et al. "Maganin ƙwaƙƙwara tare da hydroxychloroquine da azithromycin don waɗanda ake zargi da kamuwa da COVID-19 ta hanyar telemedicine." Afrilu 15, 2020. Shiga Afrilu 30, 2020.Download PDFTakaitawa: Duk da cewa tsananin alamun bayyanar cututtuka da cututtuka sun fi girma a cikin marasa lafiya da aka ji da su fiye da abubuwan sarrafawa, buƙatun asibiti ya ragu sosai tsakanin waɗanda ke karɓar hydroxychloroquine: 1.2% a cikin marasa lafiya waɗanda ke fara jiyya kafin ranar 7 na alamun da 3.2% ga marasa lafiya waɗanda ke fara jiyya bayan rana ta 7, idan aka kwatanta da 5.4% don sarrafawa. Ba a bayar da rahoton arrhythmias na zuciya a cikin marasa lafiya 412 da aka yi wa magani ba. |
| 5) | Szente Fonseca SN et al. "Hadarin asibiti ga marasa lafiya na Covid-19 da aka bi da su tare da tsarin magunguna daban-daban a Brazil: Nazarin kwatance." Travel Med Infect Dis 2020;38:101906. Doi: 10.1016/j.tmaid.2020.101906Download PDFTakaitawa: Nazarin marasa lafiya 717 da aka gwada-tabbatattun alamun bayyanar cututtuka sama da shekaru 40, yana nufin shekaru 51, wanda ke gabatarwa tsakanin Mayu 11 da Yuni 3, 2020 a Brazil. An daidaita shi don shekaru, jinsi, dyspnea a gabatarwa, kiba, ciwon sukari, da cututtukan zuciya, amfani da duka HCQ da prednisone tare da haɗin gwiwar rashin daidaituwa don asibiti na 0.40; amfani da HCQ kawai, rashin daidaituwa rabo = 0.45; da kuma amfani da prednisone kawai, rashin daidaituwa rabo = 0.51. |
| 6) | Ip A da al. "Hydroxychloroquine a cikin kula da marasa lafiya marasa lafiya tare da alamun COVID-19 mai sauƙi: Nazarin kallo da yawa. BMC Infect Dis 2021;21:72. Doi: 10.1186 / s12879-021-05773-wDownload PDFTakaitawa: Tsakanin Maris 1 da Afrilu 22, 2020, an gano marasa lafiya 1,274 da ba a shigar da ziyarar ER ba kuma an tabbatar da kamuwa da cutar ta SARS-CoV-2 ta gwajin PCR. 97 sun karɓi takardun magani don ko sun fara shan HCQ, kuma daga sauran 1,177, 970 sun kasance masu ƙima-madaidaici da shekaru, masu canji na alƙaluma da kuma yawan abubuwan haɗin gwiwa, suna gabatar da alamun cututtuka, alamun rashin lafiya, gwaje-gwajen dakin gwaje-gwaje na asali, da ER-ziyarar da lokutan biyo baya. Fiye da kashi uku cikin huɗu na batutuwan suna da cututtuka ko kuma sun haura shekaru 60, wanda hakan ya sa su kasance masu haɗari. A cikin binciken da ya dace da multivariate, jiyya tare da HCQ ya rage haɗarin asibiti da kashi 47%. |
| 7) | Ly TDA et al. "Tsarin kamuwa da cutar SARS-CoV-2 tsakanin tsofaffi mazauna mazaunin da ke zaune a wuraren kulawa na dogon lokaci a Marseille, Faransa, Maris-Yuni 2020." Int J Antimicrob Agents 2020;56(6):106219. Doi: 10.1016/j.ijantimicag.2020.106219Download PDFTakaitawa: Nazarin gidajen kulawa guda 23 a Marseille, Faransa wanda daga cikin mazauna 226 da suka kamu da cutar, an gano 37 saboda alamun COVID-19 da 189 ta hanyar tantance jama'a. A cikin bincike mai yawa da aka daidaita don jima'i, shekaru, amfani da iskar oxygen da yanayin ganowa (alamomi vs nunawa), karɓar HCQ+azithromycin na akalla kwanaki uku yana da alaƙa da 63% rage haɗarin mutuwa. |
| 8) | Heras E et al. " Abubuwan haɗarin mace-mace na COVID-19 a cikin tsofaffi a cikin cibiyar kulawa ta dogon lokaci." Eur Geriatr Med 2021; 12 (3): 601-607. Doi: 10.1007 / s41999-020-00432-wDownload PDFTakaitawa: Bincike ya gano marasa lafiya 100 PCR da aka tabbatar da COVID-19, matsakaicin shekaru 85, waɗanda suka karɓi HCQ+azithromycin, HCQ tare da wasu ƙwayoyin cuta kamar beta-lactam ko nau'in quinolone, ko wasu maganin rigakafi kaɗai. A cikin nazarin multivariate na rashin daidaituwar mace-mace, jiyya tare da HCQ+azithromycin vs. kawai sauran maganin rigakafi yana da OR=0.044; jiyya tare da HCQ+ wasu maganin rigakafi vs. sauran maganin rigakafi kadai yana da OR=0.32. |
| 9) | Cangiano B et al. "Mutuwar mace a cikin gidan kula da tsofaffi na Italiya yayin bala'in COVID-19: alaƙa da jinsi, shekaru, ADL, ƙarin bitamin D, da iyakancewar gwajin cutar." Shekaru 2020;12. Doi: 10.18632/tsufa.202307Download PDFTakaitacciyar: Mazauna casa'in da takwas daga cikin 157 mazauna a cikin gidan kula da tsofaffi a Milan, Italiya, matsakaicin shekaru 90, sun gwada inganci don SARS-CoV-2. A cikin tsarin jujjuyawar logistic da aka daidaita don shekaru, jima'i, fihirisar Barthel da BMI, an haɗa karɓar HCQ tare da rage mace-mace sau 7. |
| 10) | Sulaiman T. "Tasirin farfaɗo na tushen hydroxychloroquine a cikin marasa lafiya na COVID-19 a cikin saitunan kulawa na gaggawa: Nazarin ƙungiyar gama gari na ƙasa baki ɗaya." Preprints 2020. Doi: 10.1101/2020.09.09.20184143Download PDFTakaitawa: Kusan 8,000 masu matsakaicin matsakaici na PCR-tabbatacce COVID-19 da ke gabatarwa a asibitocin kula da marasa lafiya na ƙasa a Saudi Arabiya tsakanin 5-26 Yuni, 2020 an ɗauke su don yin rajista. Majinyatan da aka yi wa magani da sarrafa sun kasance daidai a cikin rarraba shekaru, jima'i da cututtuka guda tara da aka ruwaito. A cikin ƙirar ƙira iri-iri da aka daidaita don shekaru, jinsi da cututtuka, karɓar HCQ ya yanke mace-mace sau 3, yayin da aka sami raguwar ninki 5 a mace-mace tare da maganin HCQ+ zinc vs zinc kawai. |
| 11) | Cadegiani, FA et al. "Farkon COVID-19 Farkon Farko tare da Azithromycin Plus Nitazoxanide, Ivermectin ko Hydroxychloroquine a cikin Saitunan Marassa lafiya An Rage Alamomin Ciki Mai Mahimmanci Idan aka kwatanta da Sanannun Sakamako a Marasa lafiya da ba a kula da su." Sabbin ƙwayoyin cuta da Sabbin cututtuka, Yuli 7, 2021. Doi: 1016/j.nmni.2021.100915Download PDFTakaitacciyar: A cikin duka, an yi wa marasa lafiya 159 magani tare da HCQ kuma 137 sarrafawa sun shiga. Babu asibiti ko mace-mace tsakanin majinyatan HCQ, yayin da aka kwantar da marasa lafiya 27 a asibiti kuma 2 sun mutu. |
